OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2025
Diabetic Foot Ulcer (DFU) and Diabetic Foot Infection (DFI) market is set to triple in value from $292.1 Million in 2015 to $873.4 Million by 2025, representing a compound annual growth rate of 11.6%, this relatively strong growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by a number of factors. These include the rising number of patients suffering from DFU, the introduction of new drug Granexin, and an increased emphasis on the cost-effectiveness of advanced DFU treatments in preventing serious complications.
The US is the largest market for DFU, DFI therapies, contributing approximately 62% of total sales in the base year and it is estimated that a novel wound healing therapy (FirstString’s Granexin) to be the strongest driver of growth in the DFU market in the 7MM, reaching sales of $570.3M in 2025.
According to Jesus Cuaron, Senior Analyst, the DFU market is expected to experience moderate changes over the next decade, with prospects for treatments entering the space looking bleak. Currently, FirstString’s Phase III candidate Granexin is the most promising drug in the DFU space. It statistically increases the rate of 100% wound closure compared to DFU standard of care.
Indeed, a number of wound-healing pipeline agents have recently failed clinical trials, primarily due to the lack of improved efficacy compared to current DFU standard-of-care practices, including products such as CytoTools’ DermaPro, an intralesional formulation of diperoxochloric acid, and Olympus Biotech’s topical trafermin spray. Overall, the development of novel DFU products has been very risky.
The report “OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2025” provides a detail overview of DFUs and DFIs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines and analysis of the current and future market competition in the global DFU and DFI therapeutics market.
Companies mentioned in this report: Advanced BioHealing, Advanced Tissue Sciences, CoDa Therapeutics, FirstString Research, Genentech, GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Healthpoint Biotherapeutics Kaken Pharmaceutical, Lakewood-Amedex, MiMedx, Relief Therapeutics, Scios, Shire, Shire Regenerative Medicine, Smith & Nephew, Stryker Biotech, Olympus, Olympus Biotech, Organogenesis, Osiris Therapeutics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook